Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersAdnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinomaRecruitingPhase 12026-02-03NCT06469281

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Regeneron Pharmaceuticals238

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
John Theurer Cancer Center Hackensack University Medical CenterHackensackUnited States8
LDS HospitalSalt Lake CityUnited States82
Massachusetts General HospitalBostonUnited States1015
Roswell Park Cancer InstituteBuffaloUnited States9
UPMC Hillman Cancer CenterPittsburghUnited States330